secwatch / observer
8-K filed November 4, 2021, 7:59 PM ET ticker PGNY CIK 0001551306
earnings confidence high sentiment positive materiality 0.95

Progyny Reports Q3 2021 Revenue of $122.3M, Appoints Pete Anevski as CEO

Progyny, Inc.

2021-Q3 EPS reported $0.51 revenue$122,284,000

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

David Schlanger

Executive Chairman
PGNY · Progyny, Inc.
Effective
2022-01-01
Successor
Pete Anevski
Filed
November 4, 2021, 7:59 PM ET
On November 4, 2021, Progyny, Inc. (the “Company”) announced that David Schlanger plans to transition to the role of Executive Chairman, effective as of January 1, 2022
Appointed

Beth Seidenberg

Lead Independent Director
PGNY · Progyny, Inc.
Effective
2022-01-01
Filed
November 4, 2021, 7:59 PM ET
Beth Seidenberg, M.D., who currently serves as Chair of the Board, will assume the position of Lead Independent Director.
Appointed

Pete Anevski

Director
PGNY · Progyny, Inc.
Effective
2022-01-01
Filed
November 4, 2021, 7:59 PM ET
the Board has appointed Mr. Anevski as a director of the Company effective as of the date he becomes Chief Executive Officer.
Role change

Michael Sturmer

President
PGNY · Progyny, Inc.
Effective
2022-01-01
Filed
November 4, 2021, 7:59 PM ET
Michael Sturmer, 45, who currently serves as Executive Vice President, Chief Growth and Strategy Officer, will succeed Mr. Anevski as President, effective as of January 1, 2022.
Role change

Pete Anevski

Chief Executive Officer
PGNY · Progyny, Inc.
Effective
2022-01-01
Successor
Michael Sturmer
Filed
November 4, 2021, 7:59 PM ET
Pete Anevski, 54, who currently serves as President and Chief Operating Officer, will succeed Mr. Schlanger as Chief Executive Officer, effective as of January 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Schlanger changed role as Executive Chairman at Progyny, Inc..

Action
transition to
Role
Executive Chairman
Exact text from the filing
On November 4, 2021, Progyny, Inc. (the “Company”) announced that David Schlanger plans to transition to the role of Executive Chairman, effective as of January 1, 2022
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Beth Seidenberg was appointed as Lead Independent Director at Progyny, Inc..

Action
assume
Role
Lead Independent Director
Exact text from the filing
Beth Seidenberg, M.D., who currently serves as Chair of the Board, will assume the position of Lead Independent Director.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Pete Anevski was appointed as Director at Progyny, Inc..

Action
appointed
Role
Director
Exact text from the filing
the Board has appointed Mr. Anevski as a director of the Company effective as of the date he becomes Chief Executive Officer.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Sturmer changed role as President at Progyny, Inc..

Action
succeed
Role
President
Exact text from the filing
Michael Sturmer, 45, who currently serves as Executive Vice President, Chief Growth and Strategy Officer, will succeed Mr. Anevski as President, effective as of January 1, 2022.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Pete Anevski changed role as Chief Executive Officer at Progyny, Inc..

Action
succeed
Role
Chief Executive Officer
Exact text from the filing
Pete Anevski, 54, who currently serves as President and Chief Operating Officer, will succeed Mr. Schlanger as Chief Executive Officer, effective as of January 1, 2022.
View on SEC.gov

Progyny, Inc. filing history →

Source: SEC EDGAR
accession 0001558370-21-014614
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.